The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A populational change in prognosis of patients diagnosed with locally advanced melanoma: Last glimpse before the introduction of adjuvant treatment in stage IIB/C.
 
Pawel Teterycz
No Relationships to Disclose
 
Katarzyna Kozak
No Relationships to Disclose
 
Marcin Zietek
No Relationships to Disclose
 
Marcin Zdzienicki
No Relationships to Disclose
 
Magdalena Papiez
No Relationships to Disclose
 
Grazyna Kaminska-Winciorek
No Relationships to Disclose
 
Katarzyna Galwas
No Relationships to Disclose
 
Natasza Kempa-Kaminska
No Relationships to Disclose
 
Bozena Cybulska-Stopa
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; SERVIER
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - MSD; Novartis; Pierre Fabre; SERVIER
 
Lukasz Galus
No Relationships to Disclose
 
Robert Dziura
No Relationships to Disclose
 
Dariusz Nejc
No Relationships to Disclose
 
Kamil Drucis
No Relationships to Disclose
 
Michal Jankowski
No Relationships to Disclose
 
Joanna Placzke
Honoraria - Apexigen; BioNTech SE; BMS GmbH & Co. KG; IO Biotech Aps Co Syneo; MSD Oncology; Novartis/Pfizer
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; MSD Oncology; Novartis; Pierre Fabre
 
Anna Mariuk-Jarema
No Relationships to Disclose
 
Pawel Rogala
No Relationships to Disclose
 
Jerzy Mitus
No Relationships to Disclose
 
Hanna Kosela-Paterczyk
No Relationships to Disclose
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Genesis Pharma; Medison; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Philogen; Pierre Fabre
Speakers' Bureau - Novartis; Pfizer; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre